Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Acquires $20,400.00 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CEO Rachel E. Haurwitz acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were purchased at an average cost of $1.02 per share, for a total transaction of $20,400.00. Following the completion of the transaction, the chief executive officer now directly owns 3,369,395 shares in the company, valued at $3,436,782.90. The trade was a 0.60 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Caribou Biosciences Price Performance

Shares of CRBU stock traded up $0.01 during mid-day trading on Monday, hitting $1.02. The company had a trading volume of 83,205 shares, compared to its average volume of 1,603,439. Caribou Biosciences, Inc. has a 52-week low of $0.98 and a 52-week high of $5.77. The stock’s 50 day moving average price is $1.37 and its 200-day moving average price is $1.77. The company has a market capitalization of $94.40 million, a P/E ratio of -0.62 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The firm had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds have recently bought and sold shares of the business. Centric Wealth Management bought a new position in shares of Caribou Biosciences in the fourth quarter worth about $27,000. Erste Asset Management GmbH bought a new position in shares of Caribou Biosciences in the third quarter worth about $28,000. Russell Investments Group Ltd. grew its holdings in shares of Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after purchasing an additional 21,416 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after purchasing an additional 9,148 shares during the last quarter. Finally, Diametric Capital LP purchased a new stake in Caribou Biosciences in the fourth quarter worth about $42,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Citigroup lowered their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Bank of America lowered their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has a consensus rating of “Buy” and an average target price of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.